In an all-cash transaction valued at €780 million (US$920 million), Asahi Kasei Corp. offered to buy Aicuris Anti-infective Cures AG, expanding its infectious disease portfolio with a marketed ...

The effects of aging pose an additional challenge for people with HIV due to the neurological and psychological consequences ...

Researchers from Synklino A/S have published preclinical data supporting the potential of SYN-002, a targeted antiviral therapy that eliminates human cytomegalovirus (HCMV)‑infected cells by ...

Coming off a U.S. FDA approval of the first GLP-1 in pill format, Novo Nordisk A/S leaned further into oral drug delivery efforts, partnering with Vivtex Corp. to develop next-generation oral ...

United Therapeutics Corp.’s founder, chairman and CEO Martine Rothblatt disclosed during the company’s fourth-quarter earnings call Feb. 25 the “unsheathing of a category killer product” known as ...

This year, European med-tech companies continue to navigate an uncertain macro environment created by the reciprocal tariffs on goods entering the U.S., their primary market. Some companies though are ...

Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders.

Targeting an ultrarare disease affecting about 250 U.S. residents, Immedica Pharma AB’s Loargys (pegzilarginase) won accelerated FDA approval to treat hyperargininemia in those ages 2 and older with ...

GSK plc is paying $950 million cash to acquire 100% of 35Pharma Inc.’s equity and pipeline, including phase II-ready candidate HS-235 for pulmonary hypertension. The acquisition agreement comes a day ...

New hires and promotions in the biopharma and med-tech industries, including: Amber, Artiva, Boston Scientific, Diality, Helus, Human Continuum, Kyverna, Portal Access, Tectonic, Therna.

Researchers from Spyre Therapeutics Inc. reported on the therapeutic efficacy of combining anti-TL1A and anti-IL-23 antibodies in preclinical models of colitis.

Researchers from Model Medicines Inc. have presented preclinical efficacy data for MDL-001, a first-in-class, oral non-nucleoside inhibitor that targets an allosteric site in the Thumb-1 domain of the ...